Litcius/Paper detail

Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial

Jean‐Yves Blay, César Serrano, Michael C. Heinrich, John Zalcberg, Sebastian Bauer, Hans Gelderblom, Patrick Schöffski, Robin L. Jones, Steven Attia, Gina Z. D’Amato, Ping Chi, Peter Reichardt, Julie Meade, Kelvin Shi, Rodrigo Ruiz‐Soto, Suzanne George, Margaret von Mehren

2020The Lancet Oncology408 citationsDOIOpen Access PDF

Topics & Concepts

MedicineSunitinibPlaceboInternal medicineRegorafenibClinical endpointGiSTOncologyImatinibTyrosine-kinase inhibitorPopulationAdverse effectClinical trialPDGFRAImatinib mesylateCancerStromal cellPathologyColorectal cancerAlternative medicineEnvironmental healthMyeloid leukemiaGastrointestinal Tumor Research and TreatmentGastrointestinal Bleeding Diagnosis and TreatmentGastrointestinal disorders and treatments
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial | Litcius